Edition:
United Kingdom

Urogen Pharma Ltd (URGN.OQ)

URGN.OQ on NASDAQ Stock Exchange Global Market

47.57USD
14 Nov 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$47.57
Open
$47.57
Day's High
$47.88
Day's Low
$45.25
Volume
48,643
Avg. Vol
24,033
52-wk High
$68.91
52-wk Low
$36.66

Chart for

About

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for... (more)

Overall

Beta: --
Market Cap(Mil.): $381.96
Shares Outstanding(Mil.): 13.01
Dividend: --
Yield (%): --

Financials

  URGN.OQ Industry Sector
P/E (TTM): -- 85.49 33.64
EPS (TTM): -- -- --
ROI: -- -0.29 14.22
ROE: -- 0.40 15.99

Israel's UroGen to start mid-stage bladder cancer trial

RAANANA, Israel Israel's UroGen Pharma plans to begin a mid-stage trial of its treatment for bladder cancer patients in August, after positive interim results last month from an advanced trial of a treatment for upper urinary tract cancer.

21 Jun 2018

INTERVIEW-Israel's UroGen to start mid-stage bladder cancer trial

RAANANA, Israel, June 21 Israel's UroGen Pharma plans to begin a mid-stage trial of its treatment for bladder cancer patients in August, after positive interim results last month from an advanced trial of a treatment for upper urinary tract cancer.

21 Jun 2018

BRIEF-Urogen Pharma Announces Positive Interim Results From Pivotal Phase 3 Olympus Trial Of UGN-101

* UROGEN PHARMA ANNOUNCES POSITIVE INTERIM RESULTS FROM PIVOTAL PHASE 3 OLYMPUS TRIAL OF UGN-101 (MITOGEL™) FOR NON-SURGICAL TREATMENT OF UPPER TRACT UROTHELIAL CANCER (UTUC)

21 May 2018

Earnings vs. Estimates